Published in Ann N Y Acad Sci on September 01, 2007
Overview of immunosuppression in liver transplantation. World J Gastroenterol (2009) 0.96
Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C. World J Gastroenterol (2010) 0.90
Management practices of hepatitis C virus infected alcoholic hepatitis patients: A survey of physicians. World J Gastrointest Pharmacol Ther (2013) 0.81
Management of Multiple Myeloma Complicated by Hepatitis C Virus Reactivation: The Role of New Antiviral Therapy. Open Forum Infect Dis (2015) 0.80
Challenges of recurrent hepatitis C in the liver transplant patient. World J Gastroenterol (2014) 0.77
Virus-drug interactions--molecular insight into immunosuppression and HCV. Nat Rev Gastroenterol Hepatol (2012) 0.77
Alcoholic hepatitis and concomitant hepatitis C virus infection. World J Gastroenterol (2014) 0.77
Methotrexate is not associated with increased liver cirrhosis in a population-based cohort of rheumatoid arthritis patients with chronic hepatitis C. Sci Rep (2016) 0.75
Role of LncRNA-AF085935, IL-10 and IL-17 in Rheumatoid Arthritis Patients With Chronic Hepatitis C. J Clin Med Res (2017) 0.75
Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med (2002) 8.72
Management in patients with liver cirrhosis and an umbilical hernia. Surgery (2007) 4.09
Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc Natl Acad Sci U S A (2013) 2.99
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst (2010) 2.79
Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg (2007) 2.78
End-to-end versus end-to-side esophagogastrostomy after esophageal cancer resection: a prospective randomized study. Ann Surg (2011) 2.56
Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). Anesth Analg (2002) 2.41
Cytokine gene polymorphisms and acute liver graft rejection: a meta-analysis. Liver Transpl (2005) 2.21
Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet (2004) 2.06
Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transpl (2012) 1.98
Selective decontamination of the digestive tract to prevent postoperative infection: a randomized placebo-controlled trial in liver transplant patients. Crit Care Med (2002) 1.98
A J-shaped subcostal incision reduces the incidence of abdominal wall complications in liver transplantation. Liver Transpl (2008) 1.96
Cure of Barrett's carcinoma by ifosfamide chemotherapy. Eur J Gastroenterol Hepatol (2002) 1.92
An evaluation of prognostic factors and tumor staging of resected carcinoma of the esophagus. Ann Surg (2007) 1.79
Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg (2004) 1.79
Electrocautery therapy for refractory anastomotic strictures of the esophagus. Gastrointest Endosc (2006) 1.76
Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch (2005) 1.74
Preoperative assessment of tumor location and station-specific lymph node status in patients with adenocarcinoma of the gastroesophageal junction. World J Surg (2013) 1.64
Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl (2010) 1.59
Ingestion of acid and alkaline agents: outcome and prognostic value of early upper endoscopy. Gastrointest Endosc (2004) 1.57
Physical fitness, fatigue, and quality of life after liver transplantation. Eur J Appl Physiol (2007) 1.52
Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl (2002) 1.51
Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells. Transplantation (2009) 1.50
Intrahepatic detection of FOXP3 gene expression after liver transplantation using minimally invasive aspiration biopsy. Transplantation (2007) 1.49
Validation of a nomogram predicting complications after esophagectomy for cancer. Ann Thorac Surg (2010) 1.47
Barrett's oesophageal adenocarcinoma encompasses tumour-initiating cells that do not express common cancer stem cell markers. J Pathol (2010) 1.44
Ultrasound, computed tomography, or the combination for the detection of supraclavicular lymph nodes in patients with esophageal or gastric cardia cancer: a comparative study. J Surg Oncol (2007) 1.42
The sentinel node concept in adenocarcinomas of the distal esophagus and gastroesophageal junction. J Thorac Cardiovasc Surg (2009) 1.39
High-dose intravenous immunoglobulin does not reduce the numbers of circulating CD14(+)CD16(++) monocytes in patients with inflammatory disorders. Clin Immunol (2012) 1.39
Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol (2006) 1.39
Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol (2008) 1.35
The molecular biology of esophageal adenocarcinoma. J Surg Oncol (2005) 1.32
Comparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer. Ann Surg Oncol (2012) 1.29
Mistaken identity of widely used esophageal adenocarcinoma cell line TE-7. Cancer Res (2007) 1.27
Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer (2011) 1.27
Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. J Hepatol (2009) 1.24
Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. Mol Ther (2006) 1.24
Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi). Gut (2011) 1.21
Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology (2006) 1.10
Relaparotomy following complications of feeding jejunostomy in esophageal surgery. Dig Surg (2004) 1.07
Increased incidence of adenocarcinomas at the gastro-oesophageal junction in Dutch males since the 1990s. Eur J Gastroenterol Hepatol (2002) 1.05
The effect of nitroglycerin on microvascular perfusion and oxygenation during gastric tube reconstruction. Anesth Analg (2005) 1.03
Fatty acid composition of plasma lipids in patients with pancreatic, lung and oesophageal cancer in comparison with healthy subjects. Clin Nutr (2002) 1.03
Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. Am J Clin Pathol (2008) 1.02
Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study. Transpl Int (2011) 1.02
Epidemiology and management of chronic hepatitis E infection in solid organ transplantation: a comprehensive literature review. Rev Med Virol (2013) 1.01
Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transpl (2006) 1.01
The effect of rabbit anti-thymocyte globulin induction therapy on regulatory T cells in kidney transplant patients. Nephrol Dial Transplant (2009) 1.01
Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo. Hepatology (2012) 1.00
Delay in diagnostic workup and treatment of esophageal cancer. J Gastrointest Surg (2009) 1.00
Are cytokine gene polymorphisms related to in vitro cytokine production profiles? Liver Transpl (2003) 0.99
Porcine endogenous retrovirus infects but does not replicate in nonhuman primate primary cells and cell lines. J Virol (2002) 0.98
Patient preferences for the disclosure of prognosis after esophagectomy for cancer with curative intent. Ann Surg Oncol (2008) 0.98
Outcome of esophagectomy for cancer in elderly patients. Ann Thorac Surg (2010) 0.98
Intravenous immunoglobulins promote skin allograft acceptance by triggering functional activation of CD4+Foxp3+ T cells. Transplantation (2010) 0.96
Preoperative risk assessment and prevention of complications in patients with esophageal cancer. J Surg Oncol (2010) 0.95
Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. Ann Surg (2014) 0.95
Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl (2009) 0.95
NK cells can generate from precursors in the adult human liver. Eur J Immunol (2011) 0.94
Reduced p120ctn expression correlates with poor survival in patients with adenocarcinoma of the gastroesophageal junction. J Surg Oncol (2005) 0.94
Early and long-term morbidity after total laryngopharyngectomy. Eur Arch Otorhinolaryngol (2010) 0.93
Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation. Liver Transpl (2010) 0.93
Array comparative genomic hybridization, expression array, and protein analysis of critical regions on chromosome arms 1q, 7q, and 8p in adenocarcinomas of the gastroesophageal junction. Cancer Genet Cytogenet (2009) 0.93
Secreted factors of human liver-derived mesenchymal stem cells promote liver regeneration early after partial hepatectomy. Stem Cells Dev (2012) 0.93
Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg (2011) 0.93
Characterization of human liver dendritic cells in liver grafts and perfusates. Liver Transpl (2006) 0.92
A comparison between low-volume referring regional centers and a high-volume referral center in quality of preoperative metastasis detection in esophageal carcinoma. Am J Gastroenterol (2006) 0.92
Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation. Liver Transpl (2014) 0.91
Human plasmacytoid dendritic cells induce CD8⁺ LAG-3⁺ Foxp3⁺ CTLA-4⁺ regulatory T cells that suppress allo-reactive memory T cells. Eur J Immunol (2011) 0.90
Disturbance of the microRNA pathway by commonly used lentiviral shRNA libraries limits the application for screening host factors involved in hepatitis C virus infection. FEBS Lett (2011) 0.90
Genomic array and expression analysis of frequent high-level amplifications in adenocarcinomas of the gastro-esophageal junction. Cancer Genet Cytogenet (2006) 0.90
A prospective group sequential study evaluating a new type of fully covered self-expandable metal stent for the treatment of benign biliary strictures (with video). Gastrointest Endosc (2012) 0.89
Persistent fatigue in liver transplant recipients: a two-year follow-up study. Clin Transplant (2009) 0.89
Impact of a multidisciplinary tumour board meeting for upper-GI malignancies on clinical decision making: a prospective cohort study. Int J Clin Oncol (2011) 0.89
Protoporphyrin IX fluorescence photobleaching and the response of rat Barrett's esophagus following 5-aminolevulinic acid photodynamic therapy. Photochem Photobiol (2007) 0.89
Preoperative and early postoperative quality of life predict survival in potentially curable patients with esophageal cancer. Ann Surg Oncol (2009) 0.88
Combined antiviral activity of interferon-alpha and RNA interference directed against hepatitis C without affecting vector delivery and gene silencing. J Mol Med (Berl) (2009) 0.88
Recipient ctla-4 +49 G/G genotype is associated with reduced incidence of acute rejection after liver transplantation. Am J Transplant (2003) 0.87
mTOR signaling in liver regeneration: Rapamycin combined with growth factor treatment. World J Transplant (2013) 0.87
Neoadjuvant chemoradiotherapy for esophageal cancer: a review of meta-analyses. World J Surg (2009) 0.87